Lutonix
New drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
$225m Valuation: $225m | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Lutonix specializes in the development and commercialization of drug-coated balloons (DCBs) for angioplasty procedures. The company operates in the medical device market, primarily serving healthcare providers and medical institutions that perform vascular interventions. Lutonix's core product, the Lutonix DCB, is the first and only DCB to receive FDA approval for use in long lesions up to 300mm and dysfunctional arteriovenous (AV) fistulae. This product is designed to improve patient outcomes by reducing the need for repeat interventions compared to standard angioplasty.
Lutonix generates revenue through the sale of its DCBs, which are available in various sizes and configurations to meet the needs of different vascular conditions. The company also participates in clinical trials and maintains a global registry to provide evidence of the efficacy and safety of its products. By focusing on innovation and regulatory compliance, Lutonix aims to maintain its leadership position in the DCB market.
Keywords: drug-coated balloons, angioplasty, FDA-approved, long lesions, AV fistulae, vascular interventions, medical devices, clinical trials, global registry, healthcare providers.